Zhi Tong Cai Jing·2025-10-30 00:09Core Viewpoint - China Resources Pharmaceutical (03320) has established a limited partnership agreement to create a proposed fund of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with contributions from China Resources Pharmaceutical (Shantou) as the general partner, China Resources Double Crane as a limited partner, and China Resources Pharmaceutical Investment as a limited partner, all of which are subsidiaries of the company [1] - The total commitment from the group is RMB 123 million, accounting for approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1] Group 2: Strategic Objectives - Establishing the fund aligns with the company's strategic direction in synthetic biology [1] - The group aims to build a synthetic biology industrialization platform in Hohhot, optimizing its strategic layout in key areas [1] - The fund is expected to enhance investment channels in synthetic biology, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1] - After the fund is established, it will be accounted for as equity investment in the company's consolidated financial statements [1]